A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease
Latest Information Update: 09 Jan 2025
Price :
$35 *
At a glance
- Drugs Tafenoquine (Primary)
- Indications COVID 2019 infections; Severe acute respiratory syndrome
- Focus Therapeutic Use
- Acronyms TQ 2020_06
- Sponsors 60 Degrees Pharmaceuticals
- 21 Jun 2022 According to a 60 Degrees Pharmaceuticals media release, for strategic reasons related to a rapidly changing pandemic and competitive environment, 60P elected to terminate the study early and unblind the data from n=86 patients. Early unblinding made the study underpowered to achieve its primary statistical endpoint.
- 21 Jun 2022 Status changed from active, no longer recruiting to discontinued, according to a 60 Degrees Pharmaceuticals media release.
- 21 Jun 2022 According to a 60 Degrees Pharmaceuticals media release, the preliminary results of this study have been published in the peer-reviewed journal, New Microbes and New Infections.